What Is Alpha-2-Macroglobulin Injection Treatment?

Osteoarthritis A2M TreatmentAlpha-2-macroglobulin, or A2M, is a cartilage catabolic factor inhibitor with the power to stop the progression of osteoarthritis (OA). It’s found naturally in the blood. Treatments using A2M through Cytonics Corporation may be able to help patients with OA by preventing the breakdown and loss of cartilage. Cytonics uses its own original, breakthrough technology to administer these treatments directly to the joint space in need. Here’s what you need to know about this innovative treatment.

How Does A2M Work to Stop Osteoarthritis?

Osteoarthritis is the most common form of arthritis, and one of the most prevalent health problems today. It affects about 27 million Americans. OA is a degenerative disease in which the tissues that cover joints break down and eventually wear away completely. This results in the two bones rubbing painfully together, instead of gliding, as they do when joints are healthy. Thanks to Cytonics’ A2M injection treatment, OA doesn’t have to be forever. Recent scientific studies indicate that Cytonics’ A2M injection treatment may offer lasting protection from joint collapse.

During our A2M injection treatments, we use the molecular technology we developed to concentrate the A2M in your blood, in order to deliver high amounts to the joint space. A2M is a special inhibitor because it protects the cartilage in your body from the destructive proteins (catabolic proteases) that break down cartilage and cause OA. Treatments using A2M, such as Cytonics’ unique therapy, mimic natural processes to prevent cartilage loss, promote tissue growth, and support the restoration of a healthy joint.

A2M injections with Cytonics’ special molecular technology results in plenty of A2M available to bind and stop chemicals in joints that are responsible for causing OA. The A2M fills the joint space, captures the catabolic proteases, and neutralizes their harmful degenerative effects – effectively halting osteoarthritis and related pain in their tracks. A2M doesn’t stop there. It then works to promote the regrowth of lost or worn-away cartilage in the joint to repair damage and ultimately restore pain-free use of the joint.

A2M Injection Treatment Clinical Trials

Cytonics Corporation is the only company with patented technology for concentrating A2M. Our device uses the patient’s own blood to remove the cells and inject concentrated A2M to the affected joint.

Our special Autologous Protease Inhibitor Concentrate System has received Food and Drug Administration (FDA) approval to move onto the Investigational New Drug Clinical Trial stage for the treatment of osteoarthritis. The ongoing 2016 study indicates a strong safety profile and reduction of pain after eight weeks – a positive step for the future of alpha-2-macroglobulin injection treatments.